Finance

Pharmaceutical company announces 2003 first quarter results

Published in Cancer Weekly, June 10th, 2003

Symbollon Pharmaceuticals, Inc., reported a net loss of $166,197 or $0.04 per share for the first quarter 2003, compared to a net loss of $191,019 or $0.05 per share in the same period in 2002.

According to Symbollon, the decreased loss was attributed primarily to decreased research and development expenses and decreased general and administrative expenses, partially offset by decreased revenues from product sales and decreased interest income.

In addition to other measures, "Symbollon is actively pursuing possible government sources of funding for investigation of IoGen(TM) as a potential preventative for certain types of premenopausal breast cancer...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-06-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry